Internal Medicine, Rheumatology · Waco, TX
NPI
1073624292
Since 2006
Specialty
Internal Medicine, Rheumatology
Code 207RR0500X
Group practices
1
Medicare group memberships
Hospitals
0
Hospital affiliations
611 W Hwy 6 Ste 101
Waco, TX, 76710
Phone (254) 755-4582
Groups this clinician bills Medicare through
Medicare paid, 2024
$3.8M
267,291 services
Medicare patients, 2024
773
Average age 74
Drug cost, 2024
$13.1M
8,044 prescriptions
Company payments, 2025
$31K
From 12 companies
Procedures and visits billed to Original Medicare, 2024
In 2024, the most common Medicare service billed by Hing-Sheung E Fung was code J3262 (injection, tocilizumab, 1 mg), 92,920 times for 22 patients. In total Hing-Sheung E Fung billed 267,291 services in 52 codes, and Medicare paid $3.8M.
| Code |
|---|
Official US government data: the national provider registry and Medicare enrollment records, linked by NPI. Last update of this record: 2022-02-16.
| Setting |
|---|
| Services |
|---|
| Patients |
|---|
| Paid per service |
|---|
| Medicare paid |
|---|
| J3262 Injection, tocilizumab, 1 mg | Office | 92,920 | 22 | $4.70 | $437K |
| J0717 Injection, certolizumab pegol, 1 mg (code may be used for medicare when drug administered under the direct supervision of a physician, not for use when drug is self administered) | Office | 55,810 | 17 | $3.63 | $202K |
| J1602 Injection, golimumab, 1 mg, for intravenous use | Office | 27,900 | 35 | $8.78 | $245K |
| J3111 Injection, romosozumab-aqqg, 1 mg | Office | 26,880 | 22 | $8.56 | $230K |
| J0897 Injection, denosumab, 1 mg | Office | 16,500 | 164 | $20.28 | $335K |
| J0129 Injection, abatacept, 10 mg (code may be used for medicare when drug administered under the direct supervision of a physician, not for use when drug is self administered) | Office | 15,850 | 27 | $32.68 | $518K |
| J9312 Injection, rituximab, 10 mg | Office | 6,000 | 17 | $47.66 | $286K |
| J1745 Injection, infliximab, excludes biosimilar, 10 mg | Office | 4,200 | 13 | $20.57 | $86K |
| J1010 Injection, methylprednisolone acetate, 1 mg | Office | 1,740 | 24 | $0.10 | $176 |
| 96401 Chemotherapy Administration | Office | 810 | 195 | $53.40 | $43K |
| 96413 Chemotherapy Administration | Office | 794 | 128 | $96.94 | $77K |
| 99214 Office E&M - Established | Office | 707 | 497 | $90.38 | $64K |
| J2919 Injection, methylprednisolone sodium succinate, 5 mg | Office | 364 | 20 | $0.23 | $84.37 |
| J3301 Injection, triamcinolone acetonide, not otherwise specified, 10 mg | Office | 348 | 42 | $0.74 | $256 |
| 96415 Chemotherapy Administration | Office | 285 | 38 | $21.59 | $6,153 |
By year: 2022 $3.7M for 221,959 services; 2023 $3.4M for 228,428 services; 2024 $3.8M for 267,291 services.
Medicare prescription drug claims, 2024
In 2024, the drug Hing-Sheung E Fung prescribed most often to Medicare patients was Methotrexate (Methotrexate Sodium), with 1,370 prescriptions and refills. In total Hing-Sheung E Fung wrote 8,044 Medicare prescriptions that cost $13.1M.
| Drug | Claims | 30-day fills | Patients | Cost |
|---|---|---|---|---|
| Methotrexate Methotrexate Sodium | 1,370 | 2,454 | 353 | $36K |
| Hydroxychloroquine Sulfate Generic | 1,310 | 2,969 | 374 | $56K |
| Leflunomide Generic | 474 | 882 | 146 | $27K |
| Prednisone Generic | 330 | 532 | 83 | $2,332 |
| Folic Acid Generic | 247 | 694 | 81 | $2,601 |
| Tramadol Hcl Generic | 177 | 177 | 51 | $2,239 |
| Humira(Cf) Pen Adalimumab | 175 | 190 | 26 | $1.7M |
| Gabapentin Generic | 172 | 274 | 38 | $3,192 |
| Meloxicam Generic | 155 | 325 | 47 | $728 |
| Colchicine Generic | 153 | 296 | 51 | $8,869 |
| Tizanidine Hcl Generic | 149 | 227 | 49 | $1,595 |
| Allopurinol Generic | 149 | 375 | 47 | $2,055 |
| Rinvoq Upadacitinib | 133 | 140 | 22 | $919K |
| Celecoxib Generic | 123 | 248 | 40 | $4,360 |
| Sulfasalazine Generic | 118 | 214 | 36 | $3,535 |
Brand drugs: 1,853 claims; generic drugs: 6,125 claims; opioid claims: 207.
Money and other things of value reported by the companies
In 2025, drug and medical device companies paid Hing-Sheung E Fung $31K ($21K in general payments such as food, travel and fees and $10K for research) from 12 companies. The largest payer was Kiniksa Pharmaceuticals International, plc with $10K.
| Company | Payments | Amount |
|---|---|---|
| Kiniksa Pharmaceuticals International, plc KNSA | 3 | $10K |
| AstraZeneca Pharmaceuticals LP AZN | 11 | $8,070 |
| Amgen Inc. AMGN | 13 | $7,848 |
| Sobi, Inc SOBI.ST | 7 | $3,764 |
| Biogen, Inc. BIIB | 7 | $1,256 |
| Argenx US, Inc. ARGX | 4 | $245 |
| Janssen Scientific Affairs, LLC JNJ | 1 | $105 |
| Abbvie Inc. ABBV | 2 | $49.74 |
| Octapharma USA, Inc. | 1 | $20.51 |
Official US government data on Original Medicare services, Medicare prescription drug plans and the payments drug and device companies must report. Services with fewer than 11 patients and drugs with fewer than 11 claims are not published. Procedure codes are shown by number with their public category.